Cilastatin
From Wikipedia, the free encyclopedia
 |
|
|
Cilastatin
|
|
| Systematic (IUPAC) name | |
| 7-(2-amino-2-carboxy-ethyl)sulfanyl-2-(2,2-dimethylcyclopropyl)carbony lamino-hept-2-enoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H26N2O5S |
| Mol. mass | 358.452 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin is therefore given intravenously with imipenem in order to protect imipenem from dehydropeptidase and allow it to kill bacteria. However, cilastatin itself does not have any antibiotic activity.
[edit] See also
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
